Presentations | Y-mAbs Therapeutics, Inc.

Oct 14, 2020 · Company Presentation. January 2025. Company Presentation - January. SADA Presentation. October 2020. SADA presentation animation. Scientific Presentations. Dec 14, …

FAQs about Presentations | Y-mAbs Therapeutics, Inc. Coupon?

Who will give a corporate presentation at Y-mAbs Therapeutics?

At Y-mAbs Therapeutics' Research and Development Day in New York, Thomas Gad (Founder, President, and Interim Chief Executive Officer) will give a corporate presentation. Steen Lisby, M.D., DMSc, (SVP, Chief Scientific Officer) will present pipeline news and an overview of the investigational SADA technology platform (Liquid Radiation™). ...

How much did y-mAbs Therapeutics (ymab) earn in a quarter?

In the last reported quarter, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) earned $20.30 million and reported earnings per share of $0.15, surpassing analysts' consensus estimates of $15.55 million and $0.31 respectively. ...

Who is y-mAbs Therapeutics?

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY. ...

Where can I buy Y-mAbs Therapeutics stock?

You can purchase shares of YMAB stock through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. ...

Should you buy y-mAbs Therapeutics (ymab – research report)?

Truist Financial analyst Nicole Germino maintained a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today. The company’s shares closed last Friday at $6.89. According to TipRanks, Germino is a 5-star analyst with an average return of 36.6% and a 41.03% success rate. ...

Why did Michael Ulz give y-MABS a sell rating?

Michael Ulz has given his Sell rating due to a combination of factors pertaining to Y-Mabs Therapeutics’ current situation and future prospects. The company’s FY24 product sales are in line with expectations but only at the low end of their guidance range, indicating limited immediate growth potential. ...